A detailed history of Nuveen Asset Management, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 4,814,549 shares of BCRX stock, worth $36.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,814,549
Previous 4,495,385 7.1%
Holding current value
$36.6 Million
Previous $27.8 Million 31.71%
% of portfolio
0.01%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.41 - $8.69 $2.05 Million - $2.77 Million
319,164 Added 7.1%
4,814,549 $36.6 Million
Q2 2024

Aug 09, 2024

BUY
$4.13 - $6.79 $7.75 Million - $12.7 Million
1,875,524 Added 71.59%
4,495,385 $27.8 Million
Q1 2024

May 13, 2024

SELL
$4.89 - $7.65 $4.14 Million - $6.48 Million
-847,103 Reduced 24.43%
2,619,861 $13.3 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $4.45 Million - $6.05 Million
893,624 Added 34.73%
3,466,964 $20.8 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $10.6 Million - $12.5 Million
1,577,857 Added 158.5%
2,573,340 $18.2 Million
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $1.39 Million - $1.75 Million
199,184 Added 25.01%
995,483 $7.01 Million
Q1 2023

May 15, 2023

SELL
$7.94 - $11.84 $6.43 Million - $9.58 Million
-809,395 Reduced 50.41%
796,299 $6.64 Million
Q4 2022

Feb 14, 2023

SELL
$10.5 - $14.2 $3.12 Million - $4.22 Million
-297,127 Reduced 15.62%
1,605,694 $18.4 Million
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $248,310 - $340,822
-23,013 Reduced 1.19%
1,902,821 $24 Million
Q2 2022

Aug 15, 2022

SELL
$7.89 - $17.88 $4.19 Million - $9.5 Million
-531,381 Reduced 21.63%
1,925,834 $20.4 Million
Q1 2022

May 16, 2022

BUY
$11.56 - $19.76 $1.11 Million - $1.9 Million
96,290 Added 4.08%
2,457,215 $38.8 Million
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $768,747 - $1.06 Million
-68,761 Reduced 2.83%
2,360,925 $32.7 Million
Q3 2021

Nov 12, 2021

SELL
$14.21 - $17.65 $1.93 Million - $2.4 Million
-135,734 Reduced 5.29%
2,429,686 $34.9 Million
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $580,117 - $1.05 Million
61,065 Added 2.44%
2,565,420 $40.6 Million
Q1 2021

May 17, 2021

BUY
$7.37 - $13.61 $6.87 Million - $12.7 Million
931,841 Added 59.26%
2,504,355 $25.5 Million
Q4 2020

May 17, 2021

SELL
$3.37 - $8.61 $299,330 - $764,757
-88,822 Reduced 5.35%
1,572,514 $11.7 Million
Q4 2020

Feb 16, 2021

BUY
$3.37 - $8.61 $117,036 - $299,016
34,729 Added 2.14%
1,661,336 $12.4 Million
Q3 2020

Nov 16, 2020

SELL
$3.43 - $5.53 $206,489 - $332,911
-60,201 Reduced 3.57%
1,626,607 $5.59 Million
Q2 2020

Aug 14, 2020

SELL
$1.9 - $5.61 $179,437 - $529,814
-94,441 Reduced 5.3%
1,686,808 $8.04 Million
Q1 2020

May 14, 2020

BUY
$1.6 - $4.11 $1.14 Million - $2.93 Million
712,751 Added 66.71%
1,781,249 $3.56 Million
Q4 2019

Feb 14, 2020

BUY
$1.59 - $3.45 $390,529 - $847,375
245,616 Added 29.85%
1,068,498 $3.69 Million
Q3 2019

Nov 14, 2019

BUY
$2.5 - $3.73 $11,622 - $17,340
4,649 Added 0.57%
822,882 $2.36 Million
Q2 2019

Aug 15, 2019

BUY
$2.91 - $9.15 $2.38 Million - $7.49 Million
818,233 New
818,233 $3.1 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.